XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.1
Note 14 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2019
Oct. 11, 2019
Artegraft Inc [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 17,500      
Business Combination, Contingent Consideration, Liability, Total 400      
CardioCel and VascuCel Biologic Patches [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     $ 7,800  
Business Combination, Contingent Consideration, Liability, Total   $ 2,000   $ 7,500
CardioCel and VascuCel Biologic Patches [Member] | Audited Carve-Out Financial Statements of the Acquired Business [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     300  
CardioCel and VascuCel Biologic Patches [Member] | Third Holdback [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     2,000  
Business Combination, Contingent Consideration, Liability, Total       2,000
CardioCel and VascuCel Biologic Patches [Member] | Extension of Product Shelf Life from 36 Months to 60 Months in the First Anniversary of Closing Date [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     500  
Business Combination, Contingent Consideration, Liability, Total       500
CardioCel and VascuCel Biologic Patches [Member] | Achievement of Specified Levels of Revenues [Member]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     $ 5,000  
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]        
Assets, Fair Value Disclosure $ 0      
Fair Value, Inputs, Level 3 [Member] | CardioCel and VascuCel Biologic Patches [Member]        
Business Combination, Contingent Consideration, Liability, Total       $ 2,300